Survival of patients with colorectal or pancreatic cancer who received &lt;i&gt;UGT1A1&lt;/i&gt; genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. Here, UGT1A1 is linked to pancreatic neoplasm.